Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a significant global health burden \[[@C1]\] and is in the world\'s top three global killers. The major cause of COPD is smoking and there is an excess of cardiovascular disease seen in COPD patients as compared to those matched for smoking exposure without COPD. The prevalence of coronary artery disease (CAD) in COPD patients has been estimated at 10--38% \[[@C2], [@C3]\] with 20--50% of mortality in COPD being related to cardiovascular causes \[[@C4], [@C6]--\] The ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) observational cohort study showed that the presence of CAD in patients with COPD is associated with poor clinical outcomes \[[@C7]\].

Several mechanisms have been proposed to explain the increased risk of CAD in COPD patients. Spill-over of pulmonary inflammation to the systemic circulation has been proposed as a possible mechanism. Another proposed mechanism contributing to CAD in COPD is an increased *in vivo* platelet activation state, which plays a key role in the pathogenesis of atherothrombosis. Monocyte--platelet aggregates, a marker of platelet activation, are elevated in both patients with stable and acute exacerbation of COPD \[[@C8]\].

The use of aspirin in the primary prevention among individuals without cardiovascular disease has been shown to be associated with a lower risk of cardiovascular events and an increased risk of major bleeding \[[@C9]\]. Ticagrelor has been used in primary prevention among type 2 diabetic patients in the THEMIS (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) trial \[[@C10]\]. Preliminary results showed that ticagrelor taken in conjunction with aspirin showed a statistically significant reduction in a composite of major adverse cardiovascular events compared to aspirin alone. The role of antiplatelet therapy (APT) using aspirin and ticagrelor in the primary prevention of cardiovascular disease among COPD patients has not been evaluated previously. The aim of this early-phase trial is to evaluate the effect of antiplatelet therapy (aspirin, ticagrelor) on platelet function and explore its effect on the inflammatory markers in patients with COPD with no prior history of CAD.

Methods {#s2}
=======

Trial design {#s2a}
------------

The APPLE COPD trial is a single-centre, early-phase, 2×2 factorial, double-blind randomised controlled trial. Investigators/assessors and patients were blinded through the use of matched placebo tablets. The early-phase design allows decision-making regarding the further investigation of either aspirin or ticagrelor in late-phase trials. Full details of the trial design and analysis plan have been published previously \[[@C11]\].

Eligibility criteria specified that patients were aged ≥18 years, with ≥10 pack-years smoking history, confirmed airflow limitation on spirometry (forced expiratory volume in 1 s (FEV~1~) \<80% predicted and FEV~1~/forced vital capacity (FVC) ratio 0.7) and had given written informed consent. Exclusion criteria for the study included any condition concurrently treated through anticoagulation or APT, including aspirin or ticagrelor; specific contraindications to management with antiplatelet medication; or aspirin and ticagrelor use. The trial was carried out in accordance with the Declaration of Helsinki. The regional National Health Service (NHS) research ethics committee (REC15/NE/0155) gave approval for this trial.

Trial interventions {#s2b}
-------------------

Consenting patients were randomised using the Newcastle Clinical Trials Unit secure web-based system to ensure concealment of allocation, and allocated in a double-blind manner into one of four groups (aspirin plus placebo, ticagrelor plus placebo, aspirin plus ticagrelor (dual antiplatelet therapy (DAPT)) or placebo only) using permuted random blocks of variable length, stratified by age (≤65 years, \>65 years). Aspirin (75 mg) was administered once daily dose and ticagrelor (90 mg) twice daily for a 6-month period, provided as two 3-month supplies. Compliance to medication was assessed at 1 month, 3 months and 6 months by the research team members in the research clinic.

Outcome measures {#s2c}
----------------

The primary outcome measure consisted of inhibition (binary response, yes/no) of the ASPI test with a responder cut-off \<40 for patients randomised to aspirin, and the adenosine diphosphate (ADP) test with a responder cut-off \<46 for patients randomised to ticagrelor. Platelet aggregation induced by ADP (ADP test) or arachidonic acid (ASPI test) was assessed by whole-blood impedance aggregometry using the Multiplate device (Roche Diagnostics, Burgess Hill, UK). The ASPI test is sensitive to an inhibition of the platelet cyclo-oxygenase, which is the target of aspirin, and the ADP test is sensitive to inhibition of P~2~Y~12~, which is the target of ticagrelor.

Secondary outcome measures were changes in systemic inflammatory markers including fibrinogen, high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor (TNF)-α, interleukin (IL)-6, myeloperoxidase (MPO) from baseline to 6 months; changes in carotid intima media thickness and non-invasive measures of vascular stiffness (pulse wave velocity) from baseline to 6 months; and changes in quality of life at baseline and at 6 months were evaluated using questionnaires (Euroqol five dimensions, five levels (EQ5D-5L), St George\'s Respiratory Questionnaire for COPD Patients (SGRQ-C)). In addition, we recorded subjective reports of breathlessness using the Medical Research Council Dyspnoea (MRCD) scale. The primary safety measure was the rates of major and minor bleeding as defined by the BARC (Bleeding Academic Research Consortium) definition \[[@C12]\]. In addition, given that ticagrelor is associated with dyspnoea, assumed to be due to its adenosine-mediated effects, we monitored FEV~1~, FVC and MRCD scale as a safety outcome measure. All non-serious adverse reactions were recorded at 6-month follow-up, and serious adverse events were recorded throughout the duration of the trial until 4 weeks after trial therapy was stopped.

Statistical considerations {#s2d}
--------------------------

A Fleming--A\'Hern \[[@C13]\] early-phase design was used to investigate the roles of each intervention (aspirin, ticagrelor) in achieving a minimum level of response at 6 months worthy of further investigation. P[erl]{.smallcaps} *et al*. \[[@C14]\] reported a response rate for ticagrelor and prasugrel at 1 month of 100% and 91.3%, respectively in a non-randomised comparison in patients with myocardial infarction. APPLE COPD assumed a response rate to reject either treatment (p0) \<65% and a response rate to investigate either treatment further (p1) \>80%. The justification to investigate either treatment further is based on observing a critical number of responses for each intervention, specifically 44 for aspirin and 42 for ticagrelor according to the Fleming--A\'Hern design. The control arm provides a direct and unbiased benchmark.

With error levels of 12% α (type 1) and 12% β (type 2), inflated due to the early-phase nature of the design, the target recruitment was 50 patients per arm for each comparison within the 2×2 design, namely 1) aspirin *versus* no aspirin; 2) ticagrelor *versus* no ticagrelor. The sample size was adjusted for an anticipated 15% drop-out rate within the 6-month timeframe to a target recruitment of 120 patients.

As a 2×2 factorial design, the primary analyses are based on a comparison of aspirin *versus* no aspirin and ticagrelor *versus* no ticagrelor. Response rate was calculated on an intention to treat (ITT) basis as the total number of patients responding at 6 months as a proportion of all patients randomised, reported as an unadjusted odds ratio with 95% confidence intervals. A preplanned sensitivity analysis was carried out on the per-protocol set removing patients who have withdrawn completely, were lost to follow-up or who discontinued treatment. Adverse events are reported descriptively in terms of the number of events and number of unique patients experiencing an adverse event expressed as a proportion of the total number of patients starting treatment. Descriptive data are presented for demographics and baseline characteristics.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

120 patients were recruited. The CONSORT (Consolidated Standards of Reporting Trials) diagram is shown in [figure 1](#F1){ref-type="fig"}. Patient characteristics were balanced across arms ([table 1](#TB1){ref-type="table"} and [supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)). The mean age of patients was 67.5 years and 57 (47.5%) patients were male. The median QRISK2 score was 22.0 (interquartile range (IQR) 15.5--29.0). Of the 117 patients with current COPD medication information, 88 (75.2%) were on triple inhaled therapy (inhaled corticosteroid (ICS)/long-acting β-agonist (LABA)/long-acting muscarinic antagonist), 12 (10.3%) were on ICS/LABA, 11 (9.4%) were on LABA alone, nine (7.7%) were on long-term azithromycin and four (3.4%) were on long-term oxygen. The laboratory tests and other study related variables are shown in [table 2](#TB2){ref-type="table"} and s[upplementary table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials). FIGURE 1CONSORT (Consolidated Standards of Reporting Trials) diagram. COPD: chronic obstructive pulmonary disease; DAPT: dual antiplatelet therapy; ITT: intention-to-treat; PP: per-protocol. ^\#^: there was one administrative error, so there were 121 randomisations, of which 120 were related to patients; ^¶^: one patient attended visit but the lab samples were not suitable for analysis. TABLE 1Baseline characteristics**PlaceboAspirinTicagrelorDAPTTotalSubjects**31312929120**Age at randomisation**66.3±9.268.5±7.266.5±7.769.0±10.667.5±8.7**Male**15 (48)12 (39)15 (52)15 (52)57 (47.5)**QRISK2 score %**20 (12--28)19 (17--27)22 (14--27)24 (20--35)22.0 (15.5--28.0)**Smoking status** Nonsmoker0 (0)0 (0)0 (0)0 (0)0 (0) Ex-smoker21 (68)20 (65)21 (72)21 (72)83 (69.2) Light smoker (\<10 pack-years)3 (10)0 (0)1 (3)3 (10)7 (5.8) Moderate smoker (10--19 pack-years)5 (16)9 (29)5 (17)4 (14)23 (19.2) Heavy smoker (≥20 pack-years)2 (6)2 (6)2 (7)1 (3)7 (5.8)**Diabetes status** Type 10 (0)(0)2 (7)3 (10)5 (4.2) Type 22 (6)3 (10)2 (7)3 (10)10 (8.3)**Angina or heart attack in a first-degree relative aged \<60 years? Yes**10 (32)6 (19)7 (24)9 (31)32 (26.7)**On blood pressure treatment? Yes**10 (32)9 (29)12 (41)13 (45)44 (36.7)**Rheumatoid arthritis? Yes**0 (0)1 (3)3 (10)1 (3)5 (4.2)**Cholesterol/HDL ratio**3.0 (2.2--4.0)2.8 (2.4--4.1)3.0 (2.6--3.6)3.1 (2.4--3.6)2.9 (2.4--3.8)**Systolic blood pressure mmHg**145.7 (16.1)144.6 (18.2)143.1 (14.7)144.5 (22.1)144.5 (17.7)**Height cm**167.5 (9.9)163.0 (10.5)164.6 (11.3)166.9 (10.9)165.5 (10.7)**Weight cm**74.7 (18.2)73.1 (17.4)72.2 (18.7)79.9 (18.5)74.9 (18.2)**BMI kg·m^−2^**26.5 (5.4)27.4 (5.6)26.5 (5.7)28.9 (7.0)27.3 (6.0)**COPD disease category**^\#^ Severe (FEV~1~ \<30% pred)8 (27)6 (19)6 (21)5 (17)25 (21.0) Moderate (FEV~1~ 30--49% pred)10 (33)14 (45)7 (24)11 (38)42 (35.3) Mild (FEV~1~ 50--79% pred)12 (40)11 (35)16 (55)13 (45)52 (43.7)**Daily sputum producer \>3 months in each of last 2 year? Yes**22 (71)15 (48)18 (62)15 (52)70 (58.3)**Number of acute exacerbations of COPD treated in past 12 months**4.2 (4.5)3.4 (3.1)2.6 (3.1)2.5 (2.0)3.2 (3.3)**Number of hospitalisation in past 12 months for COPD**0.6 (1.2)0.4 (1.6)0.4 (0.9)0.2 (1.0)0.4 (1.2)Data are presented as n, mean±[sd]{.smallcaps}, n (%) or median (interquartile range). DAPT: dual antiplatelet therapy; HDL: high-density cholesterol; BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV~1~: forced expiratory volume in 1** **s. ^\#^: National Institute for Health and Care Excellence Clinical guideline (June 2010). TABLE 2Laboratory and other secondary outcomes data**PlaceboAspirinTicagrelorDAPTTotalSubjects**31312929120**Haemoglobin g·L^−1^**146.4±13.3145.4±14.5146.1±13.0141.8±16.6144.9±14.4**White blood cell count ×10^9^ cells·L^−1^**8.6±2.68.6±2.38.8±2.28.3±1.98.6±2.2**Platelet count ×10^9^ cells·L^−1^**284.3±77.2280.6±61.0284.9±65.7281.6±71.8282.9±68.4**Neutrophil count ×10^9^ cells·L^−1^**5.7±2.35.6±2.05.6±1.85.3±1.85.2 (4.3--6.4)**Monocytes ×10^9^ cells·L^−1^**0.73±0.420.64±0.210.70±0.190.67±0.230.60 (0.50--0.80)**Eosinophil count ×10^9^ cells·L^−1^**0.24±0.170.20±0.150.18±0.120.24±0.190.19 (0.11--0.31)**Urea mmol·L^−1^**4.7±1.25.4±2.15.0±2.35.9±1.85.2±1.9**Creatinine µmol·L^−1^**76.1±14.971.4±14.076.1±20.086.9±19.277.5±17.9**Fibrinogen g·L^−1^**3.9±0.83.7±0.73.9±0.83.7±0.94.0 (3.0--4.0)**hsCRP mg·L^−1^**7.8±15.43.6±3.58.2±16.53.8±3.82.5 (1.2--5.6)**TNF-α pg·mL^−1^**2.38±2.732.35±2.591.52±1.231.44±1.501.00 (0.70--2.14)**IL-6 pg·mL^−1^**5.81±5.645.96±6.183.82±3.043.39±1.613.43 (2.26--5.20)**MPO ng·mL^−1^**814.38±480.41013.17±578.5785.53±453.5702.53±324.3773.63 (420.40--1173.66)**Vascular stiffness m·s^−1^**9.74±1.909.91±2.499.23±1.239.87±2.589.69±2.11**CIMT maximum mm**1.0±0.21.0±0.31.0±0.21.0±0.21.0±0.2**MRC dyspnoea scale**3.6±1.03.7±1.13.4±1.33.3±1.23.5±1.1 10 (0)1 (3)3 (10)2 (7)6 (5.0) 27 (23)4 (13)4 (14)7 (24)22 (18.3) 34 (13)6 (19)6 (21)4 (14)20 (16.7) 415 (48)13 (42)10 (34)12 (41)50 (41.7) 55 (16)7 (23)6 (21)4 (14)22 (18.3)**EQ5D-5L index**0.619±0.2610.676±0.2220.662±0.2210.675±0.2530.658±0.238**EQ5D health score**61.8±20.459.3±16.666.6±18.160.9±17.562.1±18.2**SGRQ-C current health** Very good2 (6)0 (0)0 (0)0 (0)2 (1.7) Good4 (13)5 (17)10 (34)8 (28)27 (22.7) Fair18 (58)18 (60)12 (41)14 (48)62 (52.1) Poor4 (13)7 (23)6 (21)6 (21)23 (19.3) Very poor3 (10)0 (0)1 (3)1 (3)5 (4.2)**SGRQ-C symptom score**73.6±22.272.3±18.460.2±24.867.3±19.768.5±21.8**SGRQ-C activity score**74.2±27.374.8±24.667.7±24.262.8±30.870.1±27.0**SGRQ-C impact score**45.2±26.742.5±20.140.0±25.242.2±27.242.5±24.7**SGRQ-C total**59.1±23.957.7±19.153.0±21.853.0±25.255.8±22.5Data are presented as n, mean±[sd,]{.smallcaps} median (interquartile range) or n (%). DAPT: dual antiplatelet therapy; hsCRP: high-sensitivity C-reactive protein; TNF: tumour necrosis factor; IL: interleukin; MPO: myeloperoxidase; CIMT: carotid intima media thickness; MRC: Medical Research Council; SGQR-C: St George\'s Respiratory Questionnaire for COPD patients.

Treatment received {#s3b}
------------------

All 120 randomised patients started treatment. The median (IQR) time on treatment from randomisation across all arms was 182 (175--189) days ([supplementary table S3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)). Treatment compliance was high, with 91% and 88% of the 102 participants who reached 6 months taking ≥80% of the protocol dose for aspirin/placebo aspirin and ticagrelor/placebo ticagrelor, respectively ([supplementary table S4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)).

Primary outcome measure {#s3c}
-----------------------

The ITT and per-protocol analysis of the primary outcome measure is shown in [table 3](#TB3){ref-type="table"}. In the 60 patients randomised to aspirin, at 6 months, there were 29 (48.3%, 95% CI 35.8--61.0%) ASPI responders observed in the ITT analysis. This rate is lower than anticipated in the statistical design and did not reach the critical threshold of 44 responders required to warrant further research, according to the Fleming--A\'Hern design. In the 58 patients randomised to ticagrelor, there were 24 (41.4%, 95% CI 29.3--54.6%) ADP responders observed in the ITT analysis. This rate is lower than anticipated in the design and did not reach the critical threshold of 42 responders required to warrant further research. [Figure 2a](#F2){ref-type="fig"} shows a reduction in ASPI from baseline in the aspirin group at 1 month and 6 months, but no reduction in the no aspirin group. There was more variation in the aspirin group at 6 months as shown by the IQR. A reduction in ADP is observed in the ticagrelor group at 1 and 6 months compared to baseline. This reduction was not seen in the no-ticagrelor group. There is larger variation in the ADP score at 6 months in the ticagrelor group ([figure 2b](#F2){ref-type="fig"}).

###### 

Primary outcome measures

                                **Aspirin**       **No aspirin**     **Ticagrelor**    **No ticagrelor**
  -------------------------- ------------------ ------------------- ----------------- -------------------
  **ITT analysis set**^\#^           60                 60                 58                 62
   Baseline                          1                   6                  4                  1
  1.7 (0.2--11.3)              10 (4.5--20.8)     6.9 (2.6--17.3)    1.6 (0.2--10.9)  
   6 months                          29                  7                 24                  2
  48.3 (35.8--61)             11.7 (5.6--22.8)   41.4 (29.3--54.6)   3.2 (0.8--12.3)  
  **PP analysis set**^¶^             41                 45                 32                 54
   6 months                          28                  7                 22                  2
  68.3 (52.3--80.9)           15.6 (7.5--29.6)   68.8 (50.4--82.6)   3.7 (0.9--14.0)  

Data are presented as n or % (95% CI). ITT: intention-to-treat; PP: per-protocol. ^\#^: descriptive statistics for the primary outcome of response for the comparative groups at baseline and 6 months for the ITT analysis set; ^¶^: response is ASPI response in the aspirin and no-aspirin columns and adenosine diphosphate response in the ticagrelor and no-ticagrelor columns.

![Primary outcome measure intention-to-treat (ITT) analysis. Boxplots of the a) ASPI test split by no-aspirin and aspirin comparative groups over time; b) adenosine diphosphate (ADP) test split by no-ticagrelor and ticagrelor comparative groups over time (ITT analysis set). i) Baseline; ii) 1 month; iii) 6 months. The green dashed line indicates the threshold below which patients are considered to be responders.](00110-2019.02){#F2}

As a prespecified sensitivity analysis, we calculated the rate of response on a per-protocol analysis set consisting of 86 (72%) of the 120 randomised participants ([figure 1](#F1){ref-type="fig"}). In the aspirin group there were 28 (68.3%, 95% CI 52.3--80.9%) ASPI responders observed ([table 3](#TB3){ref-type="table"}). In the ticagrelor group there were 22 (68.8%, 95% CI 50.4--82.6%) ADP responders observed. The larger variation in response at 6 months compared to 1 month is reduced for both the aspirin and ticagrelor groups when the data is summarised on the per-protocol analysis set ([figure 3](#F3){ref-type="fig"}). [Supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials) shows that the larger variability present in the aspirin and ticagrelor groups is from the DAPT arm.

![Primary outcome measure per-protocol analysis. Boxplots of the a) ASPI test split by no-aspirin and aspirin comparative groups over time; b) adenosine diphosphate (ADP) test split by no-ticagrelor and ticagrelor comparative groups over time with patients who withdrew, discontinued treatment or lost to follow-up by the timepoint of interest removed (per-protocol analysis set). i) Baseline; ii) 1 month; iii) 6 months. The green dashed line indicates the threshold below which patients are considered to be responders.](00110-2019.03){#F3}

Secondary outcome measures {#s3d}
--------------------------

There were no observed differences between the groups in the changes in quality of life using questionnaires (EQ5D-5L, SGRQ-C) from baseline to 6 months ([figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}, respectively). There were no clinically significant differences in changes in inflammatory markers including fibrinogen, hsCRP, TNF-α, IL-6 and MPO from baseline to 6 months and there were no clinically significant differences in changes in carotid intima media thickness and non-invasive measures of vascular stiffness from baseline to 6 months in the different groups ([supplementary figures](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials) S2, S3, S4).

![Secondary outcome measure St George\'s Respiratory Questionnaire for chronic obstructive pulmonary disease patients (SGRQ-C). Boxplots of SGRQ-C total score over time by comparative groups split by a) no aspirin and aspirin and b) no ticagrelor and ticagrelor (intention-to-treat analysis set). i) Baseline; ii) 1 month; iii) 6 months.](00110-2019.04){#F4}

![Secondary outcome measure Euroqol five-dimensions (EQ5D) health score over time by comparative groups split by a) no aspirin and aspirin and b) no ticagrelor and ticagrelor (intention-to-treat analysis set). i) Baseline; ii) 1 month; iii) 6 months.](00110-2019.05){#F5}

Safety outcomes {#s3e}
---------------

Five type 1 bleeds according to the BARC criteria were recorded in this study: two in the placebo arm, two in the aspirin arm and one in the ticagrelor arm. They were all categorised as minimal on the Thrombolysis in Myocardial Infarction scale ([supplementary table S5](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)). Dyspnoea was measured using the MRCD scale, where a score of 1 equates to minimal breathlessness and 5 equates to housebound due to breathlessness. The MRCD score was similar across the groups and at all time points. This was also the case for FEV~1~ and FVC ([supplementary table S6](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)).

Adverse events and serious adverse events {#s3f}
-----------------------------------------

The adverse events are shown in [supplementary table S7](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials). During the study, one participant, who was in the DAPT arm, experienced a severe adverse event that was considered to be definitely treatment related. This adverse event was breathlessness and the treatment was discontinued. There were 31 serious adverse events in 10 patients (8%, n=120), none of which were considered to be related to treatment ([supplementary table S8](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00110-2019.figures-only#fig-data-supplementary-materials)).

Discussion {#s4}
==========

Increasingly it is accepted that COPD is a complex multisystems disorder \[[@C15]\]. In addition to neuropsychiatric morbidity, metabolic syndrome, obesity and diabetes, COPD has been shown to be linked with systemic inflammation, thrombocytosis and activation of prothrombotic pathways \[[@C16]\]. The end result of these is an elevated risk of CAD. However, to date there are few studies specifically targeting the excess CAD risk in COPD patients. Cardiovascular complications in COPD are one of the most costly comorbidities \[[@C17]\].

Our data are novel in that they demonstrate in the per-protocol analysis that just over two-thirds of patients with COPD demonstrated platelet response to antiplatelet therapies compared to 100% of patients with myocardial infarction \[[@C14]\]. Interestingly, we noted that for both ASPI and ADP tests \>30% of patients in the per-protocol analysis did not demonstrate platelet response to therapeutic targeting based on recognised thresholds in the primary prevention setting in our population. High on-treatment platelet reactivity despite use of P~2~Y~12~ antagonists is associated with adverse cardiac events \[[@C18]\]. A previous study in the setting of secondary prevention showed that COPD patients who underwent percutaneous coronary intervention have higher "on treatment" platelet reactivity compared to non-COPD patients and suggested that this could contribute to the high cardiovascular mortality in these patients \[[@C19]\]. Reassuringly, our data demonstrate that there were mean response rates in ADP and ASPI tests that were very similar at 1 month and 6 months, suggesting that the effects were sustained.

We noted more withdrawals in those treated with ticagrelor than those treated with aspirin alone or placebo. Despite the significant airflow limitation seen in this group only one patient had an adverse event reported as severe breathlessness requiring drug discontinuation. The withdrawal rates were higher in the ticagrelor arms, but were similar to those reported in a previous study of ticagrelor where nearly 11% of patients stopped therapy due to dyspnoea \[[@C20]\]. Nevertheless, we observed reduced platelet response in patients receiving aspirin as well as those receiving ticagrelor, suggesting that this is a true reflection of response not merely due to drug compliance in our COPD patients. Importantly, our further per-protocol analysis (excluding patients who have withdrawn completely, were lost to follow-up or who discontinued treatment) showed that \>30% of patients did not demonstrate the required platelet response to antiplatelet therapy.

Several commercially available validated tests are used to evaluate platelet response to therapy. In our study we used the Multiplate test, which has previously been shown to be concordant with VerifyNow and vasodilator stimulated phosphoprotein (VASP) tests. The Multiplate test has been shown to best reflect the *in vivo* plasma concentrations of ticagrelor and its active metabolite compared to other tests (VerifyNow and VASP) \[[@C21]\]. Other studies have shown Multiplate, VASP and platelet function analyser tests to have moderate agreement regarding the classification of patients as responders to P~2~Y~12~ inhibition \[[@C22]\]. Therefore, the Multiplate test is a valid method of evaluating platelet response to antiplatelet therapy in our patient cohort. Of note, platelet reactivity values have not been shown to be predictive of cardiovascular morbidity and mortality \[[@C23]\]. Our study was not designed to evaluate cardiovascular morbidity and mortality.

One of the key concerns in initiating antiplatelet therapy in primary prevention is bleeding. We specifically sought known side-effects of antiplatelet therapy such as bleeding (aspirin and ticagrelor) and dyspnoea (ticagrelor). In our study we did not identify any clinically significant bleeding in patients receiving antiplatelet therapy. This might be due to the fact that our study had small number of patients and were treated with antiplatelet therapy for 6 months. Previous studies have shown that ticagrelor-related dyspnoea is usually mild or moderate in intensity and does not appear to be associated with differences concerning any efficacy or safety outcomes with ticagrelor compared with clopidogrel therapy \[[@C24]\]. In our study we did not observe clinically significant dyspnoea in our patient cohort. These findings support the safety of using antiplatelet therapy in the primary prevention in patients with COPD. In a previous *post hoc* analysis, COPD patients experienced high rates of ischaemic events compared to non-COPD patients. Ticagrelor *versus* clopidogrel substantially decreased the absolute risk of ischaemic events (5.8%) in COPD patients, without increasing overall major bleeding events \[[@C25]\]. Based on previous studies, we anticipated a close to 100% platelet response to ticagrelor in our patient cohort. However, this was not demonstrated in our study. These findings support the high prothrombotic milieu in COPD patients, where in addition to potent antiplatelet therapy, an antithrombotic therapy might be beneficial in addressing the excess cardiovascular morbidity and mortality. Of note, although several serious adverse events were recorded in our study, reassuringly none of these events were related to the drugs utilised in our study as such.

There were no improvements or decrements in the quality of life responses on antiplatelet therapy raising the potential for long-term studies. Of note, in a previous study, short-term administration of high doses of ticagrelor did not appear to alter pulmonary function at rest and during exercise in subjects at risk of (healthy elderly) or with respiratory impairment (mild asthma or mild-to-moderate COPD) \[[@C26]\]. Neurohormonal activation and systemic inflammation have been suspected to play a significant role in increasing the risk of cardiovascular disease \[[@C27], [@C29]\]. Ticagrelor as compared to clopidogrel is superior in improving surrogate markers of endothelial function and on-treatment platelet reactivity \[[@C30]\]. In our study, antiplatelet therapy did not have any clinically significant effect on any of the secondary outcome measures including inflammatory biomarkers.

Strengths and limitations {#s4a}
-------------------------

The strengths of our study included the recruitment of patients with COPD who were representative of a secondary care cohort with many patients with severe airflow limitation and multiple comorbidities. The average QRISK2 score was \>20%, confirming the fact that increased cardiovascular risk is prevalent in this population.

Our study is limited by small sample size and short duration of antiplatelet therapy. However, although this sample is not powered to address hard end-points, it is sufficiently powered to detect differences in platelet reactivity between the groups. In our study we specifically included patients without prior history of cardiovascular disease. Use of antiplatelet therapy has already been studied in patients with COPD and cardiovascular disease. There is no consensus on the optimal duration to assess antiplatelet therapy when long-term treatment is planned. We chose a 6-month period as a pragmatic time point to ascertain the effects and side effects of more prolonged therapy. Reflecting the chronic nature of COPD, long-term treatment regimens will be needed to derive cardiovascular protection and hence other time points (≥12 months) may have been equally important. Despite randomisation, the biomarker values were not evenly distributed at baseline in our study. Nevertheless, we did not demonstrate any differences in biomarker levels between baseline values and during follow-up in the different groups. This might also be attributed to small sample size in our study.

Conclusion {#s4b}
----------

Platelet response (the predefined cut-off of platelet inhibition measured using the Multiplate test) to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third of patients in the per-protocol analysis. Bruising is a common side-effect, but clinically significant bleeding is uncommon. Some patients experience dyspnoea on ticagrelor, but this is mild or moderate in the majority of patients. These findings support the high prothrombotic milieu in COPD patients where in addition to potent antiplatelet therapy, an antithrombotic therapy might be beneficial in addressing the excess cardiovascular morbidity and mortality warranting further investigation.
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